Syngene International Limited — Updates, 23-01-2025: Press Release

**Financial Highlights:**

Syngene International Limited reported a robust third-quarter performance with revenue from operations increasing by 11% year-on-year to ₹944 crores, and profit after tax (PAT) rising by 18% to ₹131 crores. Notably, operating EBITDA margins improved to 30.1% from 27.1% in the previous year, reflecting strong operational efficiency and cost control.

**Strategic Initiatives and Growth Drivers:**

The company is witnessing significant momentum in their Discovery Services division, with initial "China+1" projects transitioning into longer-term agreements. This growth is complemented by steady demand in the Contract Development and Manufacturing Organization (CDMO) business, especially in biologics.

**Business Developments:**

Syngene achieved a landmark by becoming the first in the Indian pharma sector to receive the 5S certification for its biologics quality control lab, emphasizing its commitment to quality and operational excellence.

**Market Position and Competitive Advantage:**

The positive growth trajectory suggests stabilizing market dynamics, particularly in the US biotech sector, enhancing Syngene's competitive positioning.

**Investor Implications:**

With a strong pipeline and a focus on digital initiatives, Syngene is anticipated to maintain growth momentum into the next quarter, presenting a favorable outlook for investors seeking opportunities in the burgeoning biotech market.